Moderna shares tumble on slashed sales guidance
Bio Pharma Dive
JANUARY 13, 2025
The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV vaccines.
Bio Pharma Dive
JANUARY 13, 2025
The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV vaccines.
Pharmaceutical Technology
JANUARY 13, 2025
NVIDIA starts 2025 by announcing a trio of partnerships and a research collaboration to boost healthcare sector presence.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
JANUARY 13, 2025
Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar depression.
Pharmaceutical Technology
JANUARY 13, 2025
After selling its PI3K program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the biotechs current shareholders.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
JANUARY 13, 2025
The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new company holding its employees and other assets.
Pharmaceutical Technology
JANUARY 13, 2025
CEO Albert Bourla expressed modest optimism for Pfizers 2025 revenues at JPM 2025, supported by plans to prioritize R&D in oncology and obesity.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
JANUARY 13, 2025
The proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvaes launch in postpartum depression.
Bio Pharma Dive
JANUARY 13, 2025
Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's also unlikely to appease broader investor concerns.
Pharmaceutical Technology
JANUARY 13, 2025
Gilead and LEO Pharma have entered into a strategic collaboration to expedite the latters STAT6 programmes.
Rethinking Clinical Trials
JANUARY 13, 2025
From left to right: Dr. Rachel Winer, Dr. Amanda Petrik, and Dr. Jasmin Tiro, principal investigators of the STEP-2 trial The NIH Pragmatic Trials Collaboratory is pleased to welcome the STEP-2 trial (Self-Testing for Cervical Cancer in Priority Populations) to its portfolio of innovative NIH Collaboratory Trials. Only half of eligible patients in US federally qualified health centers were screened for cervical cancer in 2021.
Pharmaceutical Technology
JANUARY 13, 2025
IDRxs lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal tumours.
Bio Pharma Dive
JANUARY 13, 2025
How clinical services organizations are overcoming challenges in the APAC market.
Pharmaceutical Technology
JANUARY 13, 2025
Johnson & Johnson (J&J) is in discussions to acquire Intra-Cellular Therapies in the biggest biotech transaction in more than a year.
Pharma Times
JANUARY 13, 2025
Companies aim to provide new treatments for inflammatory conditions
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
JANUARY 13, 2025
Regenerative medicine is an exciting field with a promising future, capable of tackling inherent challenges seen with current therapies.
Pharma Times
JANUARY 13, 2025
Survey finds AI to enhance productivity and cut costs in the next 12 months
Pharmaceutical Technology
JANUARY 13, 2025
Mediar has entered into a global licensing agreement with Eli Lilly to progress MTX-463 into a Phase II trial for the treatment of IPF.
pharmaphorum
JANUARY 13, 2025
GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.
Pharmaceutical Technology
JANUARY 13, 2025
Nano milling is a vital technique for developing fine particle-sized drug formulations and improving bioavailability of water-soluble APIs.
XTalks
JANUARY 13, 2025
Roche has announced the FDA clearance of its VENTANA Kappa and Lambda Dual in-situ hybridisation (ISH) mRNA Probe Cocktail assay, which is designed to aid in diagnosing B-cell lymphoma, a cancer that develops in white blood cells specifically B lymphocytes or B cells of the immune system. The test, the first of its kind, offers a highly sensitive method to differentiate between a B-cell malignancy and a reactive immune response.
pharmaphorum
JANUARY 13, 2025
Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs, cueing up an IPO.
Pharma Times
JANUARY 13, 2025
Companies aim to provide new treatments for inflammatory conditions
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
JANUARY 13, 2025
Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project.
Drug Patent Watch
JANUARY 13, 2025
Biosimilars have emerged as a game-changing force, promising to revolutionize patient access to life-saving biologics while simultaneously reducing healthcare costs. As we delve into the intricate world of biosimilar market dynamics, we’ll explore how these complex molecules are reshaping treatment paradigms across diverse patient populations.
pharmaphorum
JANUARY 13, 2025
Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.
Pharmaceutical Commerce
JANUARY 13, 2025
The acquisition features Caplyta as part of its neuroscience portfolio, which is considered the only FDA-approved treatment for bipolar I and II depression as a monotherapy and adjunctive treatment.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
JANUARY 13, 2025
Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion Therapeutics.
Pharmaceutical Commerce
JANUARY 13, 2025
The latest news for pharma industry insiders.
pharmaphorum
JANUARY 13, 2025
Discover how data science and AI are set to revolutionise the life sciences industry by 2025, with a focus on mRNA technology and CRISPR gene editing. Stay ahead of the curve with these cutting-edge advancements.
Pharmaceutical Commerce
JANUARY 13, 2025
In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Mark Jara, founder and CTO, RxS, explains the value of an online portal that offers logistics flexibility.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content